Filtrato per argomento
Ultime notizie e aggiornamenti pharmaceuticals dalla Svizzera. Articoli curati dall'IA che coprono argomenti pharmaceuticals.
← Mostra tutte le notizietrade
A year after the EFTA-India trade agreement took effect, Swiss watch exports are benefiting from tariff reductions while pharmaceutical companies continue to seek stronger intellectual-property protections.
8 days ago · 1 source
healthcare
More than 700 medicines are affected by supply bottlenecks in Switzerland, prompting calls for stronger federal action.
Le News
Roche
Roche plans to use artificial intelligence to accelerate drug discovery and development, with as many as 20 new active substances potentially reaching the market by 2030.
SWI swissinfo.ch
Roche
Roche says its experimental obesity treatment cut average body weight by 15. 5% after 48 weeks at the highest dose in a mid-stage trial involving overweight or obese patients with type 2 diabetes. Analysts called the results competitive but said larger Phase 3 trials are needed.
SWI swissinfo.ch
Switzerland
Basel-based Lonza plans to build a spray-drying production facility in Bend, Oregon, due to open in 2029 and create more than 80 jobs. The investment is designed to expand the company’s US pharmaceutical manufacturing capabilities.
SWI swissinfo.ch
Novartis
Novartis shares fell sharply after a clinical trial failure involving a muscle-disorder treatment acquired through Avidity Biosciences. The report should assess what the setback means for investor confidence, Novartis’s pipeline strategy and the wider risks of pharmaceutical acquisitions.
SWI swissinfo.ch
Novartis
Novartis shares fell sharply after a clinical trial for a muscle-disorder treatment failed, prompting analysts to question confidence in the company’s recently acquired drug pipeline. The setback illustrates the financial and scientific risks behind major pharmaceutical acquisitions.
SWI swissinfo.ch
Switzerland
Switzerland’s economy grew 1. 5% in the second quarter, its strongest quarterly expansion since late 2021. The rebound was driven by chemicals and pharmaceuticals, a sharp recovery in exports and stronger investment, although household consumption remained subdued.
SWI swissinfo.ch
Novartis
Novartis plans to cut up to 130 jobs in Basel by the end of 2027 as it ends small-scale biologics production at its Kleinbasel site. Some activities will move to the company’s campus across the Rhine, highlighting continuing restructuring in Swiss pharmaceuticals.
SWI swissinfo.ch
China
Chinese biotechnology companies are increasingly targeting Europe as they seek licensing deals, investment and commercial growth beyond a crowded domestic market. Their expansion presents both partnership opportunities and fresh competition for Swiss pharmaceutical groups such as Roche and Novartis.
SWI swissinfo.ch · +1 more
Novartis
Novartis has suspended several experimental CAR-T cell therapy trials after three patients died from a rare, potentially fatal immune complication. The decision raises fresh questions about the risks and oversight of next-generation treatments for autoimmune disease.
SWI swissinfo.ch
Novartis
Novartis has halted several experimental CAR-T cell-therapy trials after three patients died from immune-related complications.
SWI swissinfo.ch
pharmaceuticals
An industry-backed study warns that changes to US pharmaceutical policy could cost Switzerland almost CHF95 billion by 2040. The scenarios include production moving to the United States and a new US approach to drug pricing, with potential consequences for Swiss growth and patients.
SWI swissinfo.ch
Geneva
Three Geneva-based non-profit drug developers are joining forces as funding for global health innovation comes under pressure. Their work includes treatments for malaria in newborns, hepatitis C and drug-resistant infections that commercial pharmaceutical companies have often neglected.
SWI swissinfo.ch
Roche
Roche subsidiary Genentech has secured worldwide rights, outside South Korea, to develop and market Hanmi Pharmaceutical’s experimental obesity treatment HM17321. The agreement could be worth up to $2. 3 billion, although the drug remains in early-stage clinical trials.
SWI swissinfo.ch
pharmaceuticals
A new Swiss debate is emerging over the pharmaceutical industry’s future as US pricing pressure threatens the development and availability of new medicines in Switzerland. Industry representatives warn that weaker framework conditions could reduce the sector’s economic contribution and tax revenues.
SWI swissinfo.ch
Bern
CSL Behring has completed a restructuring at its Bern site that eliminated just under 10% of jobs, although more than 100 new roles were created during the transformation. The company says the changes are intended to strengthen the site’s long-term competitiveness.
SWI swissinfo.ch
business
In a major development for the Swiss pharmaceutical sector, South Korean contract manufacturer Samsung Biologics has submitted a CHF1. 5 billion cash offer to acquire Polypeptide, a key Swiss producer of active pharmaceutical ingredients.
SWI swissinfo.ch
business
Australian pharmaceutical firm CSL Behring has announced plans for significant job cuts at its Bern facility. The move, reportedly affecting around 180 employees, has triggered a mandatory consultation procedure due to the scale of the planned redundancies.
SWI swissinfo.ch
pharmaceuticals
Swiss pharmaceutical exports to Russia maintain pre-war levels at CHF1. 8 billion, raising questions about medical trade during international conflicts.
SWI swissinfo.ch
